Combiderm0.05%+1%+0.1%

Combiderm is a topical combination indicated for the treatment of corticosteroid-responsive inflammatory dermatoses that are complicated, or suspected to be complicated, by secondary bacterial and fungal (dermatophyte and/or candidal) infection. This is a guideline-supported combination-therapy use; it is not intended for uncomplicated fungal or bacterial infections alone, for which single-agent therapy is preferred.

• Tinea corporis (ringworm of the body) with associated bacterial infection and inflammation
• Tinea cruris (jock itch) with associated bacterial infection and inflammation
• Tinea pedis (athlete's foot) with associated bacterial infection and inflammation
• Cutaneous candidiasis with secondary bacterial infection and marked inflammation
• Infected eczema and other infected, inflamed dermatoses when both antifungal and antibacterial cover plus anti-inflammatory action are required

Combiderm should be used only after appropriate clinical (and, where possible, laboratory) confirmation that both a fungal and a bacterial component are present, and only for as long as needed to control the mixed infection and inflammation.

Each gram of Betamethasone + Clotrimazole + Gentamicin cream/ointment typically contains:

• Betamethasone Dipropionate USP 0.64 mg (equivalent to Betamethasone 0.5 mg)
• Clotrimazole USP 10 mg (1% w/w)
• Gentamicin Sulfate USP equivalent to Gentamicin 1 mg (0.1% w/w)

Strengths and excipients may vary slightly by manufacturer; refer to the specific product label for the exact formulation dispensed.

Combiderm is a fixed-dose topical combination product that brings together three complementary actions in a single preparation: a potent synthetic corticosteroid (betamethasone), a broad-spectrum imidazole antifungal (clotrimazole), and an aminoglycoside antibiotic (gentamicin). It is formulated as a cream or ointment for external use on the skin and is designed specifically for mixed infections in which fungal and bacterial pathogens coexist alongside significant inflammation, itching, and discomfort.

By combining anti-inflammatory, antifungal, and antibacterial activity, Combiderm allows rapid symptomatic relief of itching, redness, and swelling while simultaneously treating the underlying microbial causes, reducing the need for multiple separate topical products.

Combiderm belongs to a therapeutic class of topical combination preparations containing a corticosteroid, an antifungal, and an antibiotic. It is classified under corticosteroid-antifungal-antibacterial combination products used in dermatology for mixed skin infections with inflammation.

Betamethasone + Clotrimazole + Gentamicin combines three distinct pharmacological mechanisms acting together at the site of application:

• Betamethasone is a potent synthetic corticosteroid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory proteins (e.g., lipocortins) and suppressing the release of inflammatory mediators, arachidonic acid derivatives, and cytokines. This produces anti-inflammatory, antipruritic, and vasoconstrictive effects that reduce redness, swelling, and itching.
• Clotrimazole is an imidazole derivative antifungal that inhibits ergosterol synthesis in the fungal cell membrane by interfering with cytochrome P450-dependent 14-alpha-demethylase, increasing membrane permeability and causing leakage of intracellular contents, leading to fungal cell death. It is active against dermatophytes (Trichophyton, Microsporum, Epidermophyton species) and Candida species.
• Gentamicin is an aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibition of protein synthesis, resulting in bactericidal activity against many gram-negative organisms and Staphylococcus aureus commonly implicated in secondary skin infections.

Together, these mechanisms allow Betamethasone + Clotrimazole + Gentamicin to control inflammation while treating both the fungal and bacterial components of a mixed skin infection.

Combiderm is for external (topical) use only. Wash and gently dry the affected area before application. Apply a thin layer and rub in gently until mostly absorbed. Wash hands after application unless the hands are the area being treated. Avoid contact with the eyes, mouth, and other mucous membranes. Do not cover the treated area with airtight or occlusive dressings unless specifically instructed by a physician, as this increases systemic absorption.

Well-verified clinically significant interactions with Combiderm are limited because systemic absorption from intact skin is normally low, but the following should be noted:

• Other topical corticosteroids or systemic corticosteroids: Concurrent use increases the risk of systemic corticosteroid side effects such as HPA-axis suppression; avoid combining with other corticosteroid-containing products on the same area.
• Other nephrotoxic or ototoxic drugs (e.g., other aminoglycosides, vancomycin, certain cephalosporins, loop diuretics such as furosemide, ethacrynic acid): If significant systemic absorption of gentamicin occurs (e.g., with prolonged use over large or damaged skin areas), concurrent systemic use of these agents may increase the risk of nephrotoxicity or ototoxicity.
• Occlusive dressings or use over large body surface areas: These increase systemic absorption of all three components and may increase the likelihood of interactions and systemic adverse effects.

Adverse effects with Combiderm are generally uncommon with short-term, correctly directed use but may occur, particularly with prolonged or extensive application:

• Local burning, stinging, or itching at the application site
• Skin redness (erythema) or irritation
• Dryness or peeling of the skin
• Contact sensitization/allergic contact dermatitis (gentamicin has some recognized potential for this with prolonged use)
• Skin atrophy, striae, telangiectasia, or hypopigmentation with prolonged use (corticosteroid-related)
• Folliculitis, miliaria, or secondary infection with prolonged occlusive use

Rare but serious effects with excessive or prolonged use include HPA-axis suppression and, very rarely with substantial systemic absorption, ototoxicity or nephrotoxicity from the gentamicin component. Patients should report persistent irritation, worsening of the condition, or signs of hearing changes promptly.

Combiderm has not been adequately studied for safety in human pregnancy. Topical corticosteroids can be absorbed systemically and may carry a theoretical risk to the fetus if used in large amounts or for prolonged periods; it should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, and only under medical advice.

It is not known whether topically applied betamethasone, clotrimazole, or gentamicin are excreted in human breast milk in clinically significant amounts. Caution is advised if used by a breastfeeding mother, particularly avoiding application to the breast area before nursing; consult a physician before use during lactation.

The following precautions apply to the use of Combiderm:

• For external use only; avoid contact with the eyes, and avoid use on the face, groin, or axillae unless specifically directed, as these areas are more prone to steroid-related skin changes.
• Avoid prolonged use, use over large body surface areas, or use with occlusive dressings, as these increase systemic absorption and the risk of HPA-axis suppression, Cushingoid features, skin atrophy, and gentamicin-related ototoxicity/nephrotoxicity.
• Use for the shortest duration necessary to control symptoms, typically not exceeding 2-4 weeks; reassess with a physician if longer treatment appears necessary. Inappropriate prolonged or repeated use of corticosteroid-antifungal combinations is a recognized cause of steroid-modified ("tinea incognito") or resistant fungal infections, so treatment should not be continued or repeated without medical reassessment.
• Not recommended for use under diapers or occlusive dressings in infants, due to increased risk of systemic absorption.
• Discontinue and consult a physician if signs of hypersensitivity, irritation, or worsening infection develop.
• Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
• Do not use on open wounds, ulcers, or for conditions not diagnosed or directed by a physician.

Significant systemic toxicity from topical overdose of Combiderm is unlikely with normal directed use, but excessive or prolonged application, especially over large areas or under occlusion, can lead to systemic absorption sufficient to cause HPA-axis suppression, Cushingoid features, or, rarely, gentamicin-related ototoxicity or nephrotoxicity. If accidental ingestion occurs or excessive application leads to systemic symptoms (such as unusual fatigue, hearing changes, or signs of adrenal suppression), seek immediate medical attention or contact a poison control center. Do not attempt to manage significant overexposure at home without professional medical guidance.

Store Combiderm at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed. Keep out of reach of children.

Pediatric patients: Children may be at greater risk than adults of HPA-axis suppression and Cushing's syndrome from topical corticosteroid absorption due to a larger skin surface area to body weight ratio. Combiderm is not recommended for children under 2 years of age, and should be used with caution, in the smallest effective amount, and for the shortest duration in older children under medical supervision.

Elderly patients: No specific dose adjustment is generally required, but skin in elderly patients may be thinner and more susceptible to corticosteroid-induced atrophy; use the minimum effective duration.

Renal or hepatic impairment: Because systemic absorption from intact skin is normally minimal, no specific dose adjustment is established for renal or hepatic impairment; however, caution is advised in patients with significant renal impairment if extensive application increases systemic gentamicin absorption, given the risk of nephrotoxicity. See Precautions and Warnings and Contraindications for further detail.

Treatment with Combiderm is typically limited to 2 weeks for body/groin infections and up to 4 weeks for tinea pedis, with reassessment by a physician if there is no improvement within 1-2 weeks. Treatment should not be continued beyond the period necessary to resolve the infection and inflammation, and repeated or prolonged courses should only occur under medical reassessment, given the risk of steroid-related skin changes and steroid-modified fungal infections.

Betamethasone + Clotrimazole + Gentamicin is a topical combination of a corticosteroid (betamethasone), an imidazole antifungal (clotrimazole), and an aminoglycoside antibiotic (gentamicin).

Betamethasone + Clotrimazole + Gentamicin works through three combined mechanisms: betamethasone suppresses local inflammatory mediators and reduces itching, redness, and swelling; clotrimazole inhibits fungal ergosterol synthesis, disrupting the fungal cell membrane and causing fungal cell death; and gentamicin binds bacterial ribosomes to inhibit protein synthesis, producing bactericidal activity against susceptible bacteria. See Pharmacology for further detail.

C

Safety and efficacy of Combiderm in children under 2 years of age have not been established, and use in this age group is not recommended. In older children, Combiderm should be used only when clearly needed, in the smallest effective amount, for the shortest possible duration, and under medical supervision, because children have a higher skin surface area to body weight ratio and are more susceptible to systemic absorption and HPA-axis suppression than adults. It should not be used under diapers or occlusive dressings in infants.